Related Experiment Video

Updated: Aug 29, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

The CDK1-Related lncRNA and CXCL8 Mediated Immune Resistance in Lung Adenocarcinoma

Jinmin Xue1,2,3, Yang Song1,2, Wenwen Xu1,2

  • 1Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.

Cells
|September 9, 2022
PubMed
Abstract

Insights

This study identifies LINC00261 as a key long non-coding RNA impacting lung adenocarcinoma (LUAD) prognosis and immunotherapy response. Its regulation with CDK1 and CXCL8 influences tumor growth and treatment efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunotherapy

Background:

  • Advanced lung adenocarcinoma (LUAD) lacks effective treatments, especially in cases without driver mutations.
  • Anti-cyclin-dependent kinase (CDK) therapies show promise, but their underlying mechanisms in LUAD require further investigation.

Purpose of the Study:

  • To elucidate the role of CDK1-associated long non-coding RNAs (lncRNAs) and immunomodulatory factors in LUAD.
  • To establish a prognostic model and understand immune resistance mechanisms in LUAD.

Main Methods:

  • Bioinformatics analysis and experimental verification to identify CDK1-related lncRNAs.
  • Single-cell, immune infiltration, and signal pathway analyses for prognostic modeling and immune resistance insights.

Main Results:

  • LINC00261, a CDK1-related lncRNA, is associated with a better prognosis in LUAD.
  • High CDK1 expression correlates with poor immunotherapy response, potentially due to CXCL8 overexpression.
  • CXCL8 levels differ between immunotherapy-responsive and resistant patients, suggesting a role in treatment outcomes.

Conclusions:

  • LINC00261, CDK1, and CXCL8 exhibit a mutual regulatory relationship influencing LUAD development.
  • This interplay affects LUAD progression and the effectiveness of immunotherapy.
Keywords:
CDK1CXCL8LINC00261lung adenocarcinoma

More Related Videos

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.3K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K